Novo Nordisk Rallies, Johnson & Johnson Slides, ServiceNow Falls
On this episode of Stock Movers:- Novo Nordisk (NVO) won approval to sell a pill version of its blockbuster obesity shot Wegovy in the US, a crucial step in its effort to defend its market share from rival Eli Lilly. The shares soared by as much as 11% in Copenhagen, the biggest intraday gain since August. Novo has fallen by almost half this year amid concern about the Danish drugmaker’s ability to compete in the obesity market it pioneered. Shares continued to rally in New York trading on Tuesday.- Johnson & Johnson (JNJ) was ordered to pay about $1.56 billion to a Maryland woman who…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.